FSD Pharma Inc. (NASDAQ:HUGE)(CSE:HUGE)(FRA:0K9A) (“FSD Pharma” or the “Company“), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders, today announced that Singular Research has initiated analyst coverage on FSD Pharma.
A copy of the report can be obtained directly from the analyst at Singular Research by contacting BJ Cook, CFA, on 818-222-6234 or at email@example.com.
FSD Pharma has not paid for this Research Report prepared by Singular Research. All reports on FSD Pharma prepared by analysts represent the views of such analysts and are not necessarily those of FSD Pharma. FSD Pharma is not responsible for the content, accuracy or timelines provided by analysts.
FSD Pharma Inc. is a biotechnology company with two candidates in different stages of development. Lucid Psychss Inc., a wholly owned subsidiary, is focused on the research and development of its lead compounds, Lucid-MS and UNBUZZD™. Lucid-MS is a molecular compound identified for the potential treatment of neurodegenerative disorders. UNBUZZD™ is a proprietary formulation of natural ingredients, vitamins, and minerals to help with liver and brain function for the purposes of potentially quickly relieving from the effects of alcohol consumption, such as inebriation, and restoring normal lifestyle.